# US 2020/0002341 A1 · Processes for preparing jak inhibitors and related intermediate compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0002341 A1
- Document ID: US20200002341A1
- Status: Published application
- Kind: A1
- Application number: 16/436,195
- Filed: 2019-06-10
- Published: 2020-01-02
- Earliest claimed: 2009-01-15
- Assignees: Incyte Holdings Corporation; Incyte Corporation
- Applicants: Incyte Holdings Corporation; Incyte Corporation
- Inventors: Jiacheng Zhou; James D. Rodgers; Haisheng Wang
- Web page: https://patentgrep.com/patent/US20200002341A1

## CPC

- C07D 487/04: Ortho-condensed systems
- C07F 5/025: {Boronic and borinic acid compounds}
- C07F 7/083: {Syntheses without formation of a Si-C bond}
- C07F 7/10: containing nitrogen {having a Si-N linkage}
- C07F 7/1892: {by reactions not provided for in C07F7/1876 - C07F7/1888}
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.

## Claims

### Claim at position 1

1-92. (canceled)

### Claim 93

A process of preparing a composition comprising an enantiomeric excess of equal to or greater than 90% of the (R)-enantiomer of a compound of formula III′:
comprising:
(a) treating a compound of Formula XI′:
with sodium hydride and N-pivaloyloxymethyl chloride to form a compound of Formula X′:
(b) treating said compound of Formula X′ with a compound of Formula XIII′:
in the presence of Pd(triphenylphosphine)4, potassium carbonate, and a solvent, to form a compound of Formula XII′:
(c) reacting said compound of Formula XII′ under deprotection conditions to give a compound of Formula IV′:
(d) reacting said compound of Formula IV″ with a compound of Formula XIV′:
in the presence of 1,8-diaza-bicyclo[5.4.0]undec-7-ene to give a compound of Formula II′:
(e) reacting said compound of Formula II′ with hydrogen gas in the presence of [Rh(COD)2]CF3SO3 and a chiral phosphine ligand selected from:
to form a compound of Formula I′:
and
(f) reacting said compound of Formula I′ under deprotection conditions to form said compound of Formula III′;
wherein * indicates a chiral carbon.

### Claim 94 (depends on 93)

The process of claim 93, further comprising preparing said compound of Formula XI′:
comprising:
(i) reacting a compound of Formula F-4:
with from about three to about five equivalents of POCl3 in the presence of about one to about two equivalents of dimethylformamide to form a compound of Formula F-3:
(ii) reacting said compound of Formula F-3 with about two equivalents of ammonia in methanol to form a compound of Formula F-2:
(iii) reacting said compound of Formula F-2 with from about 1 to about 1.5 equivalents of a Wittig-type reagent of formula [Ph3P+(CH2OCH3)]Cl—, wherein Ph is phenyl, in the presence of from about 1 to about 1.5 equivalents of potassium tert-butoxide to form a compound of Formula F-1:
and
(iv) treating said compound of Formula F-1 with aqueous concentrated hydrochloric acid in tetrahydrofuran at reflux to form compound of Formula XI′.

### Claim 95 (depends on 93)

The process of claim 93, further comprising preparing said compound of Formula XIII′:
comprising:
(i) reacting 1H-pyrazole with N-bromosuccinimide to form a compound of Formula XIX′;
(ii) protecting said compound of Formula XIX to form a compound of Formula XVIII′:
and
(iii) reacting said compound of Formula XVIII′ with about one or more equivalents of isopropylmagnesium chloride followed by treating with about one or more equivalents of compound of Formula XVII′:
to form a compound of Formula XIII′.

### Claim 96 (depends on 93)

The process of claim 93, further comprising preparing said compound of Formula XIII′:
comprising:
(i) protecting 4-iodo-1H-pyrazole to form a compound of Formula XVIII″:
and
(ii) reacting a compound of Formula XVIII″ with about one or more equivalents of a isopropylmagnesium chloride in tetrahydrofuran followed by treating with about one or more equivalents of compound of Formula XVII′:
to form a compound of Formula XIII′.

### Claim 97 (depends on 93)

The process of claim 93, wherein, in step (e):
the solvent is 2,2,2-trifluoroethanol (TFE).

### Claim at position 7

98-105. (canceled)

### Claim 106 (depends on 93)

The process of claim 93, wherein, in step (e), the hydrogenation catalyst loading is about 0.005 to about 0.01 mol %.

### Claim 107 (depends on 93)

The process of claim 93, wherein, in step (e), the ratio of said compound of Formula II to said hydrogenation catalyst is from about 20000/1 to about 10000/1.

### Claim 108 (depends on 93)

The process of claim 93, wherein, in step (e), the hydrogen pressure is from about 7 to about 60 bar.

### Claim 109 (depends on 93)

The process of claim 93, wherein, in step (e), the reaction is run at a temperature from about room temperature to about 75° C.

### Claim 110 (depends on 93)

The process of claim 93, wherein, in step (e), the reaction is run until the conversion of said compound of Formula II′ to said compound of Formula I′ is about equal to or greater than 99.5%.

### Claim 111 (depends on 93)

The process of claim 93, wherein, in step (e), the reaction is run from about 10 to about 25 hours.
